Role of Tregs in Cancer Dormancy or Recurrence

References

• Aceto N, Bardia A, Miyamoto DT, et al. (2014) Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell, 158(5), 1110–1122. doi:10.1016/j.cell.2014.07.013
   PubMed Web of Science ®Google Scholar
• Aguirre-Ghiso JA. (2007). Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer, 7(11), 834–846. doi:nrc2256[pii]
   PubMed Web of Science ®Google Scholar
• Ali FR, Lear JT. (2012). Melanoma in organ transplant recipients: Incidence, outcomes and management considerations. J Skin Cancer, 404615. doi:10.1155/2012/404615
   Google Scholar
• Atkins MB, Lotze MT, Dutcher JP, et al. (1999). High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol Off J Am Soc Clin Oncol, 17(7), 2105–2116.
   PubMed Web of Science ®Google Scholar
• Beatty GL, Paterson Y. (2000). IFN-gamma can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen. J Immunol, 165(10), 5502–5508.
   PubMed Web of Science ®Google Scholar
• Bergmann C, Wild CA, Narwan M, et al. (2011). Human tumor-induced and naturally occurring treg cells differentially affect NK cells activated by either IL-2 or target cells. Eur J Immunol, 41(12), 3564–3573. doi:10.1002/eji.201141532
   PubMed Web of Science ®Google Scholar
• Borsutzky S, Cazac BB, Roes J, Guzman CA. (2004). TGF-beta receptor signaling is critical for mucosal IgA responses. J Immunol, 173(5), 3305–3309. doi:173/5/3305 [pii]
   PubMed Web of Science ®Google Scholar
• Buell JF, Gross TG, Woodle ES. (2005). Malignancy after transplantation. Transplantation, 80(2 Suppl), S254–64. doi:00007890-200510151-00011 [pii]
   PubMed Web of Science ®Google Scholar
• Demicheli R, Miceli R, Moliterni A, et al. (2005). Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Ann Oncol Off J Eur Soc Med Oncol/ESMO, 16(9), 1449–1457. doi:mdi280[pii]
   PubMed Web of Science ®Google Scholar
• Dickerson EC, Davenport MS, Liu PS. (2015). Spontaneous regression of primary renal cell carcinoma following image-guided percutaneous biopsy. Clin Imaging, 39(3), 520–524. doi:10.1016/j.clinimag.2014.08.002
   PubMed Web of Science ®Google Scholar
• Dignass AU, Podolsky DK. (1993). Cytokine modulation of intestinal epithelial cell restitution: Central role of transforming growth factor beta. Gastroenterology, 105(5), 1323–1332. doi: S001650859300352X [pii]
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, et al. (2002). Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol, 3(11), 991–998.
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. (2004). The three Es of cancer immunoediting. Ann Rev Immunol, 22, 329–360. doi:10.1146/annurev.immunol.22.012703.104803
   PubMed Web of Science ®Google Scholar
• Engels EA, Pfeiffer RM, Fraumeni Jr, JF, et al. (2011). Spectrum of cancer risk among US solid organ transplant recipients. JAMA, 306(17), 1891–1901. doi:10.1001/jama.2011.1592
   PubMed Web of Science ®Google Scholar
• Farrar JD, Katz KH, Windsor J, et al. (1999). Cancer dormancy. VII. A regulatory role for CD8+ T cells and IFN-gamma in establishing and maintaining the tumor-dormant state. J Immunol, 162(5), 2842–2849.
   PubMed Web of Science ®Google Scholar
• Gerber SA, Sorensen EW, Sedlacek AL, et al. (2013). Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy. Immunology, 138(3), 280–292. doi:10.1111/imm.12037
   PubMed Web of Science ®Google Scholar
• Ghajar CM, Peinado H, Mori H, et al. (2013). The perivascular niche regulates breast tumour dormancy. Nat Cell Biol, 15(7), 807–817. doi:10.1038/ncb2767
   PubMed Web of Science ®Google Scholar
• Goding SR, Wilson KA, Xie Y, et al. (2013). Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J Immunol, 190(9), 4899–4909. doi:10.4049/jimmunol.1300271
   PubMed Web of Science ®Google Scholar
• Haiqi H, Yong Z, Yi L. (2011). Transcriptional regulation of Foxp3 in regulatory T cells. Immunobiology, 216(6), 678–685. doi:10.1016/j.imbio.2010.11.002
   PubMed Web of Science ®Google Scholar
• Halliday GM, Patel A, Hunt MJ, et al. (1995). Spontaneous regression of human melanoma/nonmelanoma skin cancer: Association with infiltrating CD4+ T cells. World J Surg, 19(3), 352–358.
   PubMed Web of Science ®Google Scholar
• Howe KL, Reardon C, Wang A, et al. (2005). Transforming growth factor-beta regulation of epithelial tight junction proteins enhances barrier function and blocks enterohemorrhagic Escherichia Coli O157: H7-inducedincreased permeability. Am J Pathol, 167(6), 1587–1597. doi: S0002-9440(10)61243-6 [pii]
   PubMed Web of Science ®Google Scholar
• Jensen SM, Twitty CG, Maston LD, et al. (2012). Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrence. J Immunol, 189(2), 767–776. doi:10.4049/jimmunol.1103822
   PubMed Web of Science ®Google Scholar
• Kim ST, Jeong H, Woo OH, et al. (2013). Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. Am J Clin Oncol, 36(3), 224–231. doi: 10.1097/COC.0b013e3182467d90
   PubMed Web of Science ®Google Scholar
• Kmieciak M, Gowda M, Graham L, et al. (2009). Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function. J Transl Med, 7, 89-5876-7-89. doi:10.1186/1479-5876-7-89
   PubMed Web of Science ®Google Scholar
• Kmieciak M, Knutson KL, Dumur CI, Manjili MH. (2007). HER-2/Neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. Eur J Immunol, 37(3), 675–685.
   PubMed Web of Science ®Google Scholar
• Kmieciak M, Payne KK, Idowu MO, et al. (2011). Tumor escape and progression of HER-2/Neu negative breast cancer under immune pressure. J Transl Med, 9, 35-5876-9-35.
   Web of Science ®Google Scholar
• Kmieciak M, Payne KK, Wang XY, Manjili MH. (2013). IFN-gamma ralpha is a key determinant of CD8+ T cell-mediated tumor elimination or tumor escape and relapse in FVB mouse. PloS One, 8(12), e82544.
   PubMed Web of Science ®Google Scholar
• Manjili MH. (2014). The inherent premise of immunotherapy for cancer dormancy. Cancer Res, 74(23), 6745–6749.
   PubMed Web of Science ®Google Scholar
• Manjili MH, Payne KK. (2015). Prospects in cancer immunotherapy: Treating advanced stage disease or preventing tumor recurrence? Discovery Med, 19(107), 427–431.
   PubMed Web of Science ®Google Scholar
• Menon MP, Eaton KD. (2015). Spontaneous regression of non-small-cell lung cancer in AIDS after immune reconstitution. J Thoracic Oncol Off Publ Int Assoc Study Lung Cancer, 10(1), e1–2. doi: 10.1097/JTO.0000000000000236
   Google Scholar
• Muto S, Owada Y, Inoue T, et al. (2015). Clinical significance of expanded Foxp3(+) Helios(-) regulatory T cells in patients with non-small cell lung cancer. Int J Oncol, 47(6), 2082–2090. doi: 10.3892/ijo.2015.3196
   PubMed Web of Science ®Google Scholar
• Payne KK, Keim RC, Graham L, et al. (2016). Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells. J Leukocyte Biol. doi: jlb.5A1215-580R [pii]
   PubMed Web of Science ®Google Scholar
• Penn I. (1988). Tumors of the immunocompromised patient. Ann Rev Med, 39, 63–73. doi: 10.1146/annurev.me.39.020188.000431
   PubMed Web of Science ®Google Scholar
• Planchon SM, Martins CA, Guerrant RL, Roche JK. (1994). Regulation of intestinal epithelial barrier function by TGF-beta 1. Evidence for its role in abrogating the effect of a T cell cytokine. J Immunol, 153(12), 5730–5739.
   PubMed Web of Science ®Google Scholar
• Printz C. (2001). Spontaneous regression of melanoma may offer insight into cancer immunology. J Natl Cancer Inst, 93(14), 1047–1048.
   PubMed Web of Science ®Google Scholar
• Roers A, Siewe L, Strittmatter E, et al. (2004). T cell-specific inactivation of the interleukin 10 gene in mice results in enhanced T cell responses but normal innate responses to lipopolysaccharide or skin irritation. J Exp Med, 200(10), 1289–1297. doi:jem.20041789 [pii]
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Yamaguchi T, Nomura T, Ono M. (2008). Regulatory T cells and immune tolerance. Cell, 133(5), 775–787. doi:10.1016/j.cell.2008.05.009
   PubMed Web of Science ®Google Scholar
• Sayour EJ, McLendon P, McLendon R, et al. (Apr, 2015). Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. Cancer Immunol Immunother CII, 64(4), 419–427. doi:10.1007/s00262-014-1651-7
   PubMed Web of Science ®Google Scholar
• Suzuki H, Onishi H, Morisaki T, et al. (2013). Intratumoral FOXP3+VEGFR2+ regulatory T cells are predictive markers for recurrence and survival in patients with colorectal cancer. Clin Immunol (Orlando, Fla.), 146(1), 26–33. doi:10.1016/j.clim.2012.10.007
   PubMed Web of Science ®Google Scholar
• Tokunaga E, Okano S, Nakashima Y, et al. (2014). Spontaneous regression of breast cancer with axillary lymph node metastasis: A case report and review of literature. Int J Clin Exp Pathol, 7(7), 4371–4380.
   PubMed Web of Science ®Google Scholar
• Vajdic CM, McDonald SP, McCredie MR, et al. (2006). Cancer incidence before and after kidney transplantation. JAMA, 296(23), 2823–2831. doi:296/23/2823 [pii]
   PubMed Web of Science ®Google Scholar
• Vajdic CM, van Leeuwen MT. (2009). Cancer incidence and risk factors after solid organ transplantation. Int J Cancer, 125(8), 1747–1754. doi:10.1002/ijc.24439
   PubMed Web of Science ®Google Scholar
• Wang J, Ioan-Facsinay A, van der Voort EI, et al. (2007). Transient expression of FOXP3 in human activated nonregulatory CD4+ T Cells. Eur J Immunol, 37(1), 129–138. doi:10.1002/eji.200636435
   PubMed Web of Science ®Google Scholar
• Whiteside TL, Letessier E, Hirabayashi H, et al. (1993). Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck. Cancer Res, 53(23), 5654–5662.
   PubMed Web of Science ®Google Scholar
• Ziegler SF. (2007). FOXP3: Not just for regulatory T cells anymore. Eur J Immunol, 37(1), 21–23. doi:10.1002/eji.200636929
   PubMed Web of Science ®Google Scholar